Cytek Biosciences, Inc.
Income Statement
| Line Item | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Sep 2020 | Jun 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.2M | $35.1M | $-86.9M | $34.4M | $30.4M | $24.3M | $25.1M | $19.1M |
| Cost of Revenue | $15.6M | $14.9M | $15.3M | $13.1M | $10.7M | $9.8M | $9.5M | $10.9M |
| Gross Profit | $24.6M | $20.2M | $23.6M | $21.3M | $19.7M | $14.5M | $15.6M | $8.3M |
| Gross Margin | 61.2% | 57.5% | -27.2% | 61.9% | 64.9% | 59.7% | 62.2% | 43.2% |
| Operating Expenses | ||||||||
| Research & Development | $8.4M | $8.0M | $7.1M | $6.1M | $6.2M | $5.1M | $3.4M | $2.9M |
| SG&A Expense | $8.6M | $7.5M | $6.9M | $5.7M | $4.2M | $4.0M | $1.7M | $2.5M |
| Operating Income | $-891.0K | $-2.4M | $1.3M | $2.9M | $3.8M | $1.1M | $6.7M | $-218.0K |
| Operating Margin | -2.2% | -6.7% | -1.5% | 8.4% | 12.5% | 4.7% | 26.7% | -1.1% |
| Interest Expense | $647.0K | $590.0K | $492.0K | $441.0K | $433.0K | $375.0K | $2.0K | $1.0K |
| Pretax Income | $-1.4M | $-3.3M | $444.0K | $2.1M | $3.3M | $152.0K | $6.9M | $192.0K |
| Income Tax Expense | $-699.0K | $-1.1M | $1.6M | $655.0K | $597.0K | $50.0K | $357.0K | $-7.9M |
| Net Income | $-702.0K | $-2.2M | $-1.2M | $1.4M | $2.7M | $102.0K | $6.5M | $8.1M |
| Net Margin | -1.7% | -6.2% | 1.3% | 4.1% | 8.8% | 0.4% | 26.1% | 42.4% |
| EPS (Basic) | $0.00 | $0.02 | $0.00 | $0.00 | $0.00 | $0.00 | $0.02 | $0.02 |
| EPS (Diluted) | $0.00 | $0.02 | $0.00 | $0.00 | $0.00 | $0.00 | $0.02 | $0.02 |
| Shares Outstanding (Basic) | 134.4M | 133.9M | 76.7M | 325.0M | 95.6M | 94.7M | 86.1M | 85.5M |
| Shares Outstanding (Diluted) | 134.4M | 133.9M | 81.5M | 340.9M | 108.5M | 107.3M | 93.2M | 93.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |